journal article·2024-06Open access

HOXA‐AS2 Epigenetically Inhibits HBV Transcription by Recruiting the MTA1‐HDAC1/2 Deacetylase Complex to cccDNA Minichromosome

YiPing Qin, JiHua Ren, HaiBo Yu, Xin He, ShengTao Cheng, WeiXian Chen, Zhen Yang, FengMing Sun, ChunDuo Wang, SiYu Yuan, Peng Chen, DaiQing Wu, Fang Ren, AiLong Huang, Juan Chen

Advanced Science· Volume 11· Issue 24

Abstract

Abstract Persistent transcription of HBV covalently closed circular DNA (cccDNA) is critical for chronic HBV infection. Silencing cccDNA transcription through epigenetic mechanisms offers an effective strategy to control HBV. Long non‐coding RNAs (lncRNAs), as important epigenetic regulators, have an unclear role in cccDNA transcription regulation. In this study, lncRNA sequencing (lncRNA seq) is conducted on five pairs of HBV‐positive and HBV‐negative liver tissue. Through analysis, HOXA‐AS2 (HOXA cluster antisense RNA 2) is identified as a significantly upregulated lncRNA in HBV‐infected livers. Further experiments demonstrate that HBV DNA polymerase (DNA pol) induces HOXA‐AS2 after establishing persistent high‐level HBV replication. Functional studies reveal that HOXA‐AS2 physically binds to cccDNA and significantly inhibits its transcription. Mechanistically, HOXA‐AS2 recruits the MTA1‐HDAC1/2 deacetylase complex to cccDNA minichromosome by physically interacting with metastasis associated 1 (MTA1) subunit, resulting in reduced acetylation of histone H3 at lysine 9 (H3K9ac) and lysine 27 (H3K27ac) associated with cccDNA and subsequently suppressing cccDNA transcription. Altogether, the study reveals a mechanism to self‐limit HBV replication, wherein the upregulation of lncRNA HOXA‐AS2, induced by HBV DNA pol, can epigenetically suppress cccDNA transcription.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Cancer-related molecular mechanisms research · Epigenetics and DNA Methylation · RNA modifications and cancer

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Institute for Viral Hepatitis Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education) Department of Infectious Diseases The Second Affiliated Hospital Chongqing Medical University Chongqing 400010 China

Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment Chongqing University Cancer Hospital Chongqing 400030 China

Key Laboratory of Clinical Laboratory Diagnostics (Ministry of Education) College of Laboratory Medicine Chongqing Medical University Chongqing 400016 China

State Key Laboratory of Ultrasound in Medicine and Engineering College of Biomedical Engineering Chongqing Medical University Chongqing 400016 China

Funding

National Key Research and Development Program of China · National Natural Science Foundation of China

References (47)

Show source-provided references
1. 10.1002/jmv.2805810.1002/jmv.28058 ↗
2. 10.1093/jnci/djp28810.1093/jnci/djp288 ↗
3. 10.1053/j.gastro.2011.12.06110.1053/j.gastro.2011.12.061 ↗
4. 10.1136/gutjnl-2014-30894310.1136/gutjnl-2014-308943 ↗
5. 10.1002/hep.2950910.1002/hep.29509 ↗
6. 10.14218/JCTH.2018.0005410.14218/JCTH.2018.00054 ↗
7. 10.1002/hep.2947910.1002/hep.29479 ↗
8. 10.1016/j.tig.2015.03.00710.1016/j.tig.2015.03.007 ↗
9. 10.1002/hep.3026610.1002/hep.30266 ↗
10. 10.3390/ijms1902057010.3390/ijms19020570 ↗
11. 10.1016/j.molcel.2011.08.01810.1016/j.molcel.2011.08.018 ↗
12. 10.1126/science.119200210.1126/science.1192002 ↗
13. 10.1016/j.molcel.2011.08.02710.1016/j.molcel.2011.08.027 ↗
14. 10.1038/nature0897510.1038/nature08975 ↗
15. 10.1002/cac2.1218110.1002/cac2.12181 ↗
16. 10.3389/fmicb.2017.0061310.3389/fmicb.2017.00613 ↗
17. 10.1002/advs.20210313510.1002/advs.202103135 ↗
18. 10.1136/gutjnl-2019-31963710.1136/gutjnl-2019-319637 ↗
19. 10.1186/1471-2334-5-9510.1186/1471-2334-5-95 ↗
20. 10.1007/s11010-006-9167-x10.1007/s11010-006-9167-x ↗
21. 10.1038/ncomms874310.1038/ncomms8743 ↗
22. 10.1016/j.molcel.2015.10.00110.1016/j.molcel.2015.10.001 ↗
23. 10.1016/j.celrep.2015.03.04310.1016/j.celrep.2015.03.043 ↗
24. 10.1038/nrm367910.1038/nrm3679 ↗
25. 10.1016/j.molcel.2010.12.01110.1016/j.molcel.2010.12.011 ↗
26. 10.1038/nsmb.231510.1038/nsmb.2315 ↗
27. 10.1074/jbc.M30295520010.1074/jbc.M302955200 ↗
28. 10.1002/hep.3235610.1002/hep.32356 ↗
29. 10.1038/s41467-018-06235-910.1038/s41467-018-06235-9 ↗
30. 10.1038/s41467-021-27539-310.1038/s41467-021-27539-3 ↗
31. 10.1128/JVI.01024-1410.1128/JVI.01024-14 ↗
32. 10.1002/hep.3128410.1002/hep.31284 ↗
33. 10.1016/j.virol.2016.08.00610.1016/j.virol.2016.08.006 ↗
34. 10.1186/gb-2005-6-13-24610.1186/gb-2005-6-13-246 ↗
35. 10.7554/eLife.7051110.7554/eLife.70511 ↗
36. 10.1053/j.gastro.2006.01.00110.1053/j.gastro.2006.01.001 ↗
37. 10.1038/s41419-020-03193-310.1038/s41419-020-03193-3 ↗
38. 10.18632/oncotarget.559910.18632/oncotarget.5599 ↗
39. 10.1038/oncsis.2016.8410.1038/oncsis.2016.84 ↗
40. 10.1186/s12974-021-02267-z10.1186/s12974-021-02267-z ↗
41. 10.1038/s41556-019-0299-010.1038/s41556-019-0299-0 ↗
42. 10.1038/nrgastro.2017.16910.1038/nrgastro.2017.169 ↗
43. 10.1038/nri157310.1038/nri1573 ↗
44. 10.1016/j.jhep.2021.02.00910.1016/j.jhep.2021.02.009 ↗
45. 10.1172/JCI5884710.1172/JCI58847 ↗
46. Chu C. · J Vis Exp · 2012 · 61 · 3912
47. 10.1016/j.redox.2013.12.02010.1016/j.redox.2013.12.020 ↗